BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17096315)

  • 21. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
    Diebold J; Seemüller F; Löhrs U
    Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Borderline epithelial tumours of the ovary--a retrospective analysis of 31 cases.
    Kane SV; Bharadwaj R; Tongaonkar HB
    Indian J Cancer; 1999 Mar; 36(1):18-31. PubMed ID: 10810551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analysis of peritoneal fluid in ovarian cancer patients.
    Parrella P; Zangen R; Sidransky D; Nicol T
    Mod Pathol; 2003 Jul; 16(7):636-40. PubMed ID: 12861058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glomeruloid peritoneal implants in ovarian serous borderline tumours--distinction between invasive and non-invasive implants and pathogenesis.
    Lee ES; Leong AS; Kim IS; Kim YS; Lee JH; Cho HY
    Histopathology; 2009 Nov; 55(5):505-13. PubMed ID: 19912356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours.
    Khalique L; Ayhan A; Weale ME; Jacobs IJ; Ramus SJ; Gayther SA
    J Pathol; 2007 Feb; 211(3):286-95. PubMed ID: 17154249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours.
    Abeln EC; Smit VT; Wessels JW; de Leeuw WJ; Cornelisse CJ; Fleuren GJ
    J Pathol; 1997 Dec; 183(4):424-31. PubMed ID: 9496259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinicopathological evaluation on ovarian serous borderline tumours and their implants].
    Guo L; Lian L; Liu T
    Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):287-90. PubMed ID: 9206182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.
    Verbruggen MB; Sieben NL; Roemen GM; Rockx DA; van Diest PJ; Verheijen RH; Dorsman JC
    Int J Gynecol Cancer; 2009 Dec; 19(9):1560-3. PubMed ID: 19955937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
    Stewart CJ; Brennan BA; Crook ML; Russell P
    Histopathology; 2007 Sep; 51(3):313-21. PubMed ID: 17727474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum.
    Bandera CA; Muto MG; Welch WR; Berkowitz RS; Mok SC
    Oncogene; 1998 Jul; 16(26):3455-9. PubMed ID: 9692553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours.
    Farrell WE; Simpson DJ; Bicknell J; Magnay JL; Kyrodimou E; Thakker RV; Clayton RN
    Br J Cancer; 1999 Apr; 80(1-2):44-50. PubMed ID: 10389976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serous borderline tumors of the ovary.
    Prat J
    Adv Clin Path; 1997 Apr; 1(2):97-102. PubMed ID: 10352473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.